Peer-Reviewed Study Updates, Explained Clearly
Result-led summaries of clinical studies that matter for telehealth research. Every update identifies the population, intervention, measured result, and limits before linking to the primary source.
20.2% average loss with tirzepatide vs. 13.7% with semaglutide
A peer-reviewed 72-week trial found greater average weight loss with tirzepatide than with semaglutide. This explains the study result—not which treatment, provider, or price is right for an individual.
14.9% average loss with semaglutide at 68 weeks
The STEP 1 trial is a foundational peer-reviewed study of once-weekly semaglutide 2.4 mg with lifestyle intervention. Its result describes an average trial outcome under a specific eligibility, dosing, and follow-up protocol—not a promise of a particular outcome from an online program.
20.9% average loss with tirzepatide at 72 weeks
SURMOUNT-1 evaluated three once-weekly tirzepatide doses with lifestyle intervention in adults without diabetes. The headline result comes from the 15 mg arm at week 72 and is an average outcome under the trial’s defined conditions.
20% lower major cardiovascular event risk with semaglutide
SELECT is a large peer-reviewed outcomes trial in a defined cardiovascular-risk population. Its 20% relative risk reduction refers to a composite endpoint in participants with established cardiovascular disease—not a general promise for everyone seeking weight management.
5.5% further loss with continued tirzepatide at 88 weeks
SURMOUNT-4 examined what happened after participants completed 36 weeks of tirzepatide treatment. It found further average loss among people who continued treatment during the randomized phase, while the placebo-switch group regained weight on average.
18.4% additional loss with tirzepatide after lifestyle program
SURMOUNT-3 studied tirzepatide after participants had first completed an intensive lifestyle program and lost at least 5% of body weight. The result reflects additional average loss under that trial structure, not a stand-alone prediction for a general online-care program.
7.9% further loss with continued semaglutide over 48 weeks
STEP 4 evaluated continued once-weekly semaglutide 2.4 mg after a 20-week lead-in. Its result is about the randomized continuation period and supports a more precise question than a generic before-and-after claim: what happened while treatment continued under the trial protocol?
15.2% average loss with semaglutide at 104 weeks
STEP 5 followed adults using once-weekly semaglutide 2.4 mg or placebo for two years alongside behavioral intervention. It offers a longer-term trial result under defined eligibility, dose, and follow-up conditions—not a forecast of what a particular online program or individual will experience.
15.8% average loss with semaglutide vs. 6.4% with liraglutide
STEP 8 compared two established weight-management medicines under a defined 68-week trial protocol. The result reports a larger average weight change with once-weekly semaglutide 2.4 mg than with once-daily liraglutide 3.0 mg, but it does not decide which medicine, provider, or program is appropriate for any individual.
20 fewer breathing interruptions/hour with tirzepatide at 52 weeks
SURMOUNT-OSA studied tirzepatide in adults who had both obesity and moderate-to-severe obstructive sleep apnea. Its primary endpoint was the apnea–hypopnea index, which measures breathing interruptions per hour of sleep. The findings are specific to that clinical population and trial design, not a replacement for sleep-apnea evaluation or personal treatment planning.
24% lower kidney-event risk with semaglutide
FLOW was a peer-reviewed kidney-outcomes trial in adults who had both type 2 diabetes and chronic kidney disease. Its headline result concerns a prespecified composite kidney outcome under a specific clinical protocol—not a general prediction for every person seeking GLP-1 care.
13.3% average loss with semaglutide in HFpEF
STEP-HFpEF evaluated weekly semaglutide 2.4 mg in people who had both obesity and symptomatic heart failure with preserved ejection fraction. It reported weight, symptom, and exercise-function results under a defined one-year protocol—not a substitute for heart-failure care or an individual treatment plan.
38% lower worsening-HF or CV-death risk with tirzepatide
SUMMIT tested tirzepatide in adults with obesity-related HFpEF, following participants for a median of two years. The headline result is a relative reduction in a composite cardiovascular-death or worsening-heart-failure endpoint under trial conditions—not a promise of outcome or access for a particular person.
13.9% average loss with semaglutide in obesity and prediabetes
STEP 10 tested once-weekly semaglutide 2.4 mg in adults who had both obesity and prediabetes. It reported a 52-week average weight and laboratory-glycaemia result under a defined eligibility, dose-escalation, counselling, and follow-up protocol—not proof of long-term diabetes prevention or a personal outcome forecast.
14.7% average loss with tirzepatide in type 2 diabetes
SURMOUNT-2 evaluated tirzepatide in adults who had both overweight or obesity and type 2 diabetes. Its headline 14.7% result is the 15 mg dose-arm average at week 72 under trial eligibility and follow-up conditions—not a result that can be assumed for people without diabetes or for a particular telehealth program.
19.7% average loss with tirzepatide at 176 weeks
This prespecified three-year SURMOUNT-1 analysis followed participants with obesity and prediabetes. It reported dose-specific average weight change and fewer diagnosed type 2 diabetes cases during the 176-week treatment period. Those findings are trial results under specific eligibility and follow-up conditions—not a personal prediction or an FDA-approved diabetes-prevention claim.
9.8% average loss with semaglutide in HFpEF and type 2 diabetes
STEP-HFpEF DM studied once-weekly semaglutide in adults who had obesity-related heart failure with preserved ejection fraction and type 2 diabetes. It found improvements in weight and a patient-reported heart-failure health-status score under a one-year trial protocol. The study is not a substitute for heart-failure or diabetes care and does not establish an HFpEF indication.
15.1% average loss with oral semaglutide at 68 weeks
OASIS 1 evaluated an oral semaglutide regimen escalated to 50 mg daily in adults without type 2 diabetes. The 68-week trial reported average weight loss under defined eligibility and lifestyle-intervention conditions. The studied 50 mg dose should not be treated as the same as the currently listed U.S. 25 mg oral maintenance dose.
16.0% average loss with semaglutide plus intensive behavioral therapy
STEP 3 tested weekly semaglutide 2.4 mg on top of an unusually intensive lifestyle protocol: an initial low-calorie meal-replacement diet plus 30 counseling visits. Its 16.0% result describes the combined trial program, not semaglutide alone, ordinary lifestyle support, or a result an online provider can promise.
13.7% average loss with semaglutide in knee osteoarthritis
STEP 9 evaluated weekly semaglutide 2.4 mg in people who had obesity, moderate knee osteoarthritis, and at least moderate knee pain. It reported weight and pain-score improvements under a 68-week protocol. The findings are not an osteoarthritis treatment recommendation or evidence that semaglutide changes joint structure or disease progression.
12.1% average loss with semaglutide at 44 weeks
STEP 7 studied weekly semaglutide 2.4 mg in a predominantly East Asian population with overweight or obesity. Its 44-week result is an average under the trial's eligibility, titration, lifestyle, and follow-up conditions—not a prediction for a particular person or program.
13.6% average loss with oral semaglutide at 64 weeks
OASIS 4 tested once-daily oral semaglutide 25 mg in adults without diabetes. The reported 64-week average describes that dose, population, lifestyle intervention, and trial follow-up—not an outcome a provider can promise or an assurance that an online program offers the studied regimen.
18.7% average loss with semaglutide 7.2 mg at 72 weeks
STEP UP compared a weekly 7.2 mg semaglutide regimen with 2.4 mg and placebo in adults with obesity without diabetes. Its 72-week results describe dose-specific trial averages under a defined protocol—not an individual outcome forecast or evidence that every provider offers the studied dose.
11.2 kg average loss with tirzepatide vs. 5.7 kg with semaglutide
SURPASS-2 directly compared three tirzepatide doses with semaglutide 1 mg in adults using metformin for type 2 diabetes. Its primary outcome was HbA1c change at 40 weeks; weight change was a secondary outcome. The result does not compare the current highest semaglutide dose, telehealth programs, or individual treatment suitability.
We use Google Analytics 4 to understand how readers find and use RxNotebook. Analytics cookies are only set with your consent. We do not use advertising cookies. See our Cookie Policy and Privacy Policy for details.